Mads Clausen

Mads Clausen led the establishment of MC2 Therapeutics and serves as Chairman of the Board. Mr. Clausen is also Executive Chairman of Applied Biomimetic Inc. (USA), a privately held developer of novel high-performance membrane technology. Further to this, he serves as a Director of the Board of the Bitten and Mads Clausen Foundation (Denmark). Mr. Clausen holds a MS in Engineering from the Technical University of Denmark, MS in Biotechnology from The Johns Hopkins University and an MBA from the London Business School.

Paul L. Berns

Paul L. Berns was appointed as President and Chief Executive Officer of Anacor Pharmaceuticals Inc. in 2014. He served as a Board member since 2012 and as Chairman since 2013. Anacor was acquired by Pfizer in June 2016. From March 2006 to September 2012, Mr. Berns served as President and Chief Executive Officer, and member of the board of directors, of Allos Therapeutics, Inc., which was acquired by Spectrum Pharmaceuticals, Inc. in September 2012. From June 2002 to July 2005, Mr. Berns was President, Chief Executive Officer and a director of Bone Care International, Inc., a specialty pharmaceutical company that was acquired by Genzyme Corporation in July 2005. From 2001 to 2002, Mr. Berns served as Vice President and General Manager of the Immunology, Oncology and Pain Therapeutics business unit of Abbott Laboratories. From 2000 to 2001, he served as Vice President, Marketing of BASF Pharmaceuticals/Knoll, which was acquired by Abbott in 2001. From 1990 to 2000, Mr. Berns held various positions, including senior management roles, at Bristol-Myers Squibb Company. Mr. Berns has been a director of Jazz Pharmaceuticals, PLC since June 2010. Mr. Berns received a B.S. in Economics from the University of Wisconsin.

Anders D. Hove, M.D.

Anders D. Hove is a managing partner at Majalin/Amzak Health, a partnership focusing on long-term investments in biotech, specialty pharma and medical device companies. Mr. Hove was most recently a managing general partner at Venrock Associates (“Venrock”), a venture capital firm, which he joined in 2004 focusing on private and public biotech investments. In 2008, Mr. Hove founded Venrock Healthcare Capital Partners, Venrock’s public fund focused on small capitalization biotech companies and late-stage private companies. From 1996 to 2003 he was a fund manager at BB Biotech, a multi-billion $ investment firm focused on public and private biotech investment, and from 2002 to 2003 Mr. Hove served as Chief Executive Officer of Bellevue Asset Management AG and as manager of BB Biotech. Mr. Hove has completed numerous structured public investments, 22 investments in private biotech or medtech companies and has served on 19 Boards. 14 of his private investments have completed an IPO and 4 companies were acquired while private. Some of the private or small cap public investments which Mr. Hove led or provided substantial contributions to include Adnexus, Alexion, Anacor, Arena, Ascendis, Aviron, Biomarin, Coherus, Dyax, Edge, Eyetech, GW Pharma, Medimmune, Neurocrine, Peak Surgical, Radius, Stemline, Tesaro, The Medicines Company, Theravance, etc. Mr. Hove previously held senior level positions in the medical, clinical and business operations of the pharmaceuticals division of Ciba-Geigy. He is currently a member of the board of directors of a number of public and private companies.

Mr. Hove received a M.Sc. in Biotechnology Engineering from the Technical University of Denmark, a M.D. from the University of Copenhagen and a M.B.A. from INSEAD in France.

Mette Vagner Johannesen

Mette Vagner Johannesen holds a MSc in Business Finance and has in her 20-year career held executive roles in finance, strategy, HR, administration and general management. For the last six years Miss Johannesen has managed the wealth of a high net individual, including identification of new investments, corporate development, structural and tax-optimization of group structure, administration and legal work. Prior to her current position, Miss Johannesen was COO of a listed property investment company, Senior Manager Consultant with KPMG and different CFO positions.

Miss Johannesen holds board seats in several companies and chairs the board in presently two companies.

Jesper J. Lange, LL.M.
Director, President

Jesper J. Lange is a co-founder of MC2 Therapeutics and joined the company from his position as partner in a major Danish law firm. In addition to his experience in M&A and commercialization of Intellectual Property Rights, Mr. Lange has substantial experience advising investors, early-stage to publicly listed companies in negotiations and international collaborations.

Mr. Lange has strong entrepreneurial skills and is focused on bringing together the expertise of people and companies globally to drive cost effective innovation and product development.

Mr. Lange holds Masters of Law (LLM) degrees from Columbia University Law School in New York and University of Aarhus, Law School, Denmark and has the right of audience before the High Court in Denmark. In addition, Mr. Lange has completed special leadership programs as an Officer of the Danish Army Reserve.